Penn’s CAR-T Treatment Shrank Brain Tumors in Patients in Clinical Trial
In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma.
PA as an Innovation Leader: Challenges and Solutions in the face of a Growing Industry
Pennsylvania legislators are working on new ways to retain young residents who too often leave the region for opportunities after receiving their education within the state.
New Proposed Federal Guidelines Could Threaten Innovation
Recently proposed guidance could expand "march-in rights" under the Bayh-Dole Act, significantly impacting the development of products from federally funded research.
ToxiSense Develops Plant-Based Alternativeto Horseshoe Crab Blood
ToxiSense is developing a plant-based alternative to test for bacterial toxins in vaccines and medical devices, which could eliminate the current need for bloodletting of horseshoe crabs.
Linnaeus Therapeutics Awarded European Patent
Linnaeus Therapeutics, Inc. announced the issuance of EP patent 3823617 by the European Patent Office (EPO) covering the pharmaceutical composition of matter for their lead compound, LNS8801.
Exyn Technologies Pioneers Drone Software for GPS-denied Environments
Exyn Technologies, a PCI Ventures portfolio company focused on multi-platform robotic autonomy, is receiving global recognition for its groundbreaking drone software.
Nia Therapeutics Raises $8.5 Million
Penn spinout Nia Therapeutics recently raised $8.5 million in an equity financing round.
2024 President’s Innovation Prize Winning Team Focused on Making Life Easier for Students with Learning Differences
The President's Innovation Prize was recently awarded to fourth year Penn Engineering students for their project Jochi.
Capstan raises $175M Series B
Proceeds from the financing will be used to advance Capstan's lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, CPTX2309, to early clinical proof-of-concept in autoimmune disorders.
iEcure Gains FDA approval to Conduct FirstGene Therapy Treatment
Utilizing ARCUS, a gene editing tool developed by Precision BioSciences, the therapy aims to provide a lifelong fix for this disease, potentially benefiting thousands of individuals in the US alone.